Intra-cellular Therapies, Inc.
Clinical trials sponsored by Intra-cellular Therapies, Inc., explained in plain language.
-
New pill aims to calm Alzheimer's psychosis in landmark trial
Symptom relief Recruiting nowThis study tests an experimental drug, ITI-1284, to see if it can safely reduce psychosis symptoms like hallucinations and delusions in people with Alzheimer's disease. About 370 participants will receive either the drug or a placebo, and doctors will track changes in symptom sev…
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New pill aims to soothe Alzheimer's agitation in major trial
Symptom relief Recruiting nowThis study tests an experimental drug called ITI-1284 to see if it can safely reduce agitation in people with Alzheimer's dementia. About 320 participants will receive either the drug or a placebo, and researchers will measure changes in agitated behaviors using a caregiver quest…
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
New pill may ease anxiety when current meds fall short
Symptom relief Recruiting nowThis study tests an experimental drug called ITI-1284 for people with generalized anxiety disorder (GAD) whose current treatment isn't working well enough. About 705 adults will receive either ITI-1284 or a placebo added to their usual therapy. The goal is to see if the drug safe…
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
New anxiety drug candidate ITI-1284 enters Mid-Stage trial
Symptom relief Recruiting nowThis study tests whether a daily tablet called ITI-1284, taken under the tongue, can help people with generalized anxiety disorder whose current treatments aren't working well enough. About 570 adults will receive either the drug or a placebo, and researchers will measure changes…
Phase: PHASE2 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Healthy volunteers needed to test new brain Drug's binding power
Knowledge-focused Recruiting nowThis study tests a single dose of ITI-1284 in 42 healthy adults aged 18-55. Researchers will use brain scans to see how much of the drug attaches to certain brain receptors. The goal is to gather safety and drug-level information, not to treat any disease.
Phase: PHASE1 • Sponsor: Intra-Cellular Therapies, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC